Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Revenue $14 million in Q1 fiscal 2026, flat year-over-year but a rebound from $12.4 million in Q4 fiscal 2025. The rebound was attributed to growth in the TOS business and contributions from the emerging data platform.
Research Services Revenue $13.7 million in Q1 fiscal 2026, contributing the majority of the total revenue.
Data Business Revenue Balance of the $14 million total revenue in Q1 fiscal 2026, showing growth as it generated sales for three consecutive quarters.
Loss from Operations (GAAP) $0.5 million in Q1 fiscal 2026 compared to income from operations of $1.3 million in Q1 fiscal 2025. The loss included $600,000 in noncash expenses such as stock-based compensation and depreciation.
Adjusted EBITDA $60,000 in Q1 fiscal 2026, down from $2 million in Q1 fiscal 2025. The decline was due to increased costs and investments in R&D and sales and marketing.
Gross Margin 43% in Q1 fiscal 2026, down from 50% in Q1 fiscal 2025. The decline was primarily due to increased outsourced lab service costs for radio labeling work, which is expected to improve as the work is brought in-house.
Operating Expenses $6 million in Q1 fiscal 2026, up $1 million year-over-year. The increase was driven by $0.6 million in R&D, $0.2 million in sales and marketing, and $0.2 million in G&A expenses.
Cash Position $10.3 million at the end of Q1 fiscal 2026, up $0.5 million from year-end. The company remains debt-free and had positive operating cash flow of $0.6 million.
Trade with 70% Backtested Accuracy
Analyst Views on CSBR
About CSBR
About the author
Champions Oncology (CSBR) Earnings Transcript
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026
Earnings Call Overview: Champions Oncology held its Q1 2026 earnings call on September 15, 2025, led by CEO Rob Brainin and CFO David Miller, discussing the company's financial performance and strategic direction.
Financial Performance: The company reported $14 million in revenue for Q1 2026, marking a recovery from previous quarter challenges, with growth primarily driven by its TOS business.
Champions Oncology aims for continuous revenue increase and improved margins as radiopharmaceuticals and data platforms progress.
Management Insights: CEO Rob Brainin highlighted a strong rebound in fiscal 2025 with record revenue of $14 million, driven by the TOS business and emerging data platform, while emphasizing the importance of strategic execution for long-term growth.
Financial Performance: The company reported a loss from operations of $0.5 million, with a gross margin decline to 43% due to increased outsourcing costs, but anticipates margin improvement as radiolabeling processes are internalized.
Outlook and Guidance: Management expects sequential revenue growth and margin expansion in Q2, maintaining a confident outlook despite challenges in the macro environment, particularly in biotech funding.
Analyst Sentiment: Analysts expressed cautious optimism regarding the data business and revenue growth, while management's tone remained confident, focusing on foundational strength and strategic continuity under the new CEO.
Champions Oncology Reports Non-GAAP EPS of $0.02, Exceeding Estimates by $0.03; Revenue of $14M Surpasses Expectations by $0.49M
Earnings Performance: Champions Oncology reported a Q1 Non-GAAP EPS of $0.02, exceeding expectations by $0.03.
Revenue Details: The company generated revenue of $14 million, reflecting a slight decline of 0.4% year-over-year, but still beating estimates by $0.49 million.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
Champions Oncology (CSBR) Earnings Transcript
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026
Earnings Call Overview: Champions Oncology held its Q1 2026 earnings call on September 15, 2025, led by CEO Rob Brainin and CFO David Miller, discussing the company's financial performance and strategic direction.
Financial Performance: The company reported $14 million in revenue for Q1 2026, marking a recovery from previous quarter challenges, with growth primarily driven by its TOS business.
Champions Oncology aims for continuous revenue increase and improved margins as radiopharmaceuticals and data platforms progress.
Management Insights: CEO Rob Brainin highlighted a strong rebound in fiscal 2025 with record revenue of $14 million, driven by the TOS business and emerging data platform, while emphasizing the importance of strategic execution for long-term growth.
Financial Performance: The company reported a loss from operations of $0.5 million, with a gross margin decline to 43% due to increased outsourcing costs, but anticipates margin improvement as radiolabeling processes are internalized.
Outlook and Guidance: Management expects sequential revenue growth and margin expansion in Q2, maintaining a confident outlook despite challenges in the macro environment, particularly in biotech funding.
Analyst Sentiment: Analysts expressed cautious optimism regarding the data business and revenue growth, while management's tone remained confident, focusing on foundational strength and strategic continuity under the new CEO.
Champions Oncology Reports Non-GAAP EPS of $0.02, Exceeding Estimates by $0.03; Revenue of $14M Surpasses Expectations by $0.49M
Earnings Performance: Champions Oncology reported a Q1 Non-GAAP EPS of $0.02, exceeding expectations by $0.03.
Revenue Details: The company generated revenue of $14 million, reflecting a slight decline of 0.4% year-over-year, but still beating estimates by $0.49 million.
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
